262 related articles for article (PubMed ID: 29923984)
1. Clinicopathological and prognostic significance of PD-L1 expression in sarcoma: A systematic review and meta-analysis.
Zheng C; You W; Wan P; Jiang X; Chen J; Zheng Y; Li W; Tan J; Zhang S
Medicine (Baltimore); 2018 Jun; 97(25):e11004. PubMed ID: 29923984
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Value of Programmed Cell Death 1 Ligand-1 in Patients With Bone and Soft Tissue Sarcomas: A Systemic and Comprehensive Meta-Analysis Based on 3,680 Patients.
Wang F; Yu T; Ma C; Yuan H; Zhang H; Zhang Z
Front Oncol; 2020; 10():749. PubMed ID: 32582532
[No Abstract] [Full Text] [Related]
3. Factors Modifying the Associations of Single or Combination Programmed Cell Death 1 and Programmed Cell Death Ligand 1 Inhibitor Therapies With Survival Outcomes in Patients With Metastatic Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-analysis.
Sati N; Boyne DJ; Cheung WY; Cash SB; Arora P
JAMA Netw Open; 2021 Jan; 4(1):e2034201. PubMed ID: 33496794
[TBL] [Abstract][Full Text] [Related]
4. Soluble PD-L1 as a Prognostic Factor for Immunotherapy Treatment in Solid Tumors: Systematic Review and Meta-Analysis.
Scirocchi F; Strigari L; Di Filippo A; Napoletano C; Pace A; Rahimi H; Botticelli A; Rughetti A; Nuti M; Zizzari IG
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430974
[TBL] [Abstract][Full Text] [Related]
5. Prognostic and Clinicopathological Value of PD-L1 in Melanoma: A Meta-Analysis.
Xu J; Wang F; Yan Y; Zhang Y; Du Y; Sun G
Am J Med Sci; 2020 Jun; 359(6):339-346. PubMed ID: 32498941
[TBL] [Abstract][Full Text] [Related]
6. The clinicopathological significance and prognostic value of programmed death-ligand 1 in prostate cancer: a meta-analysis of 3133 patients.
Shen H; Liu J; Sun G; Yan L; Li Q; Wang Z; Xie L
Aging (Albany NY); 2020 Dec; 13(2):2279-2293. PubMed ID: 33318295
[TBL] [Abstract][Full Text] [Related]
7. Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis.
Zhang C; Yang Q
Front Oncol; 2020; 10():572203. PubMed ID: 33634012
[TBL] [Abstract][Full Text] [Related]
8. Prognostic and clinicopathological value of PD-L2 in lung cancer: A meta-analysis.
Lin X; Lin K; Lin C; Liu T; Ba M; Tang Y; Wang J; Zhou L; Wang J; Xiao C
Int Immunopharmacol; 2021 Feb; 91():107280. PubMed ID: 33370681
[TBL] [Abstract][Full Text] [Related]
9. Prognostic and Clinicopathological Value of Programmed Cell Death Ligand1 Expression in Patients With Small Cell Lung Cancer: A Meta-Analysis.
Cai H; Zhang H; Jiang Y
Front Oncol; 2020; 10():1079. PubMed ID: 32670887
[No Abstract] [Full Text] [Related]
10. Prognostic value of programmed cell death ligand 1 expression in patients with intrahepatic cholangiocarcinoma: a meta-analysis.
Xian F; Ren D; Bie J; Xu G
Front Immunol; 2023; 14():1119168. PubMed ID: 37138876
[TBL] [Abstract][Full Text] [Related]
11. The predictive value of PD-L1 expression in response to anti-PD-1/PD-L1 therapy for biliary tract cancer: a systematic review and meta-analysis.
Yoon SB; Woo SM; Chun JW; Kim DU; Kim J; Park JK; So H; Chung MJ; Cho IR; Heo J
Front Immunol; 2024; 15():1321813. PubMed ID: 38605964
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological and prognostic significance of PD-L1 expression in colorectal cancer: a meta-analysis.
Wang S; Yuan B; Wang Y; Li M; Liu X; Cao J; Li C; Hu J
Int J Colorectal Dis; 2021 Jan; 36(1):117-130. PubMed ID: 32910207
[TBL] [Abstract][Full Text] [Related]
13. Correlation between PD-L1 expression ON CTCs and prognosis of patients with cancer: a systematic review and meta-analysis.
Kong D; Zhang W; Yang Z; Li G; Cheng S; Zhang K; Feng L
Oncoimmunology; 2021 Jun; 10(1):1938476. PubMed ID: 34211802
[TBL] [Abstract][Full Text] [Related]
14. Risk Analysis of Positive PD-L1 Expression and Clinicopathological Features and Survival Prognosis in Patients with Colorectal Cancer: Systematic Review and Meta-Analysis.
Tang M; Zheng Z; Shang J; Zhang S
J Healthc Eng; 2022; 2022():8212486. PubMed ID: 35449848
[TBL] [Abstract][Full Text] [Related]
15. Programmed Cell Death Ligand 1 Expression on Immune Cells and Survival in Patients With Nonmetastatic Head and Neck Cancer: A Systematic Review and Meta-analysis.
Blažek T; Petráš M; Knybel L; Cvek J; Soumarová R
JAMA Netw Open; 2023 Mar; 6(3):e236324. PubMed ID: 37000447
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 Overexpression on Tumor-Infiltrating Lymphocytes Related to Better Prognosis of Colorectal Cancer.
Wang JL; Yu T; Sun TT; Feng Y; Xiong H; Fang JY
Clin Lab; 2020 Dec; 66(12):. PubMed ID: 33337839
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of PD-L1 expression in pancreatic cancer: evidence from an updated meta-analysis.
Liu C; Fan L; Wu Q; Shi Y; Sun X
Pol J Pathol; 2023; 74(3):151-160. PubMed ID: 37955534
[TBL] [Abstract][Full Text] [Related]
18. Prognostic and Clinicopathological Significance of PD-L1 in Patients with Cholangiocarcinoma: A Meta-Analysis.
Xie Q; Wang L; Zheng S
Dis Markers; 2020; 2020():1817931. PubMed ID: 32724483
[TBL] [Abstract][Full Text] [Related]
19. Association between programmed cell death ligand 1 expression and thyroid cancer: A meta-analysis.
Wan B; Deng P; Dai W; Wang P; Dong Z; Yang C; Tian J; Hu T; Yan K
Medicine (Baltimore); 2021 Apr; 100(14):e25315. PubMed ID: 33832105
[TBL] [Abstract][Full Text] [Related]
20. Association between PD-L1 Expression and the Prognosis and Clinicopathologic Features of Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.
Shen M; Chen G; Xie Q; Li X; Xu H; Wang H; Zhao S
Urol Int; 2020; 104(7-8):533-541. PubMed ID: 32623437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]